You are here: Industry Insights > Obesity

News List

New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues Biotech Newswire
July 24, 2024
Currax Pharmaceuticals LLC announced the approval of additional manufacturing site for CONTRAVE®/MYSIMBA® in the European Union and European Union Economic Areas.
The Future of Obesity Drugs Suzanne Elvidge
July 01, 2024
By the year 2030, over a billion people could be affected by obesity, according to the World Obesity Forum.The obesity drug market value is expected to reach around $37.1 billion in 2031.
Gut Hormone-Based Pharmacotherapies for Obesity Neeta Ratanghayra
April 28, 2024
The history of pharmacotherapy for obesity is marked by a series of promising drugs that were withdrawn due to safety concerns.
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr PRNewswire
December 18, 2024
Ascletis Pharma Inc. announces encouraging efficacy results from its study in diet-induced obese (DIO) mice combining ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity.
NICE approves Wegovy™ (semaglutide) for obesity EuropeanPharmaceuticalReview
February 11, 2022
New draft guidance means thousands of obese Brits could benefit from Novo Nordisk’s Wegovy™ (semaglutide), a drug shown to improve weight loss.
New management: Promising drug for people living with obesity pharmatimes
February 08, 2022
NICE recommends appetite suppressing drug which can reduce a patient’s by more than 10%.
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity prnasia
January 18, 2022
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of patient dosing...
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH prnasia
December 29, 2021
EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that its wholly owned US subsidiary...
Bariatric Surgery Cuts Hepatic Steatosis in Obesity and T2DM Drugs
November 30, 2021
Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are highly effective for reducing hepatic steatosis in patients with severe obesity and type 2 diabetes, with almost complete clearance of liver fat one year after surgery...
Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity prnasia
November 08, 2021
Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™ (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period.